Reported results
- Revenue was $94.9 million, compared to $90.9 million in the third quarter of 2025.
- Software revenue was $48.8 million, compared to $43.8 million in the third quarter of 2025.
- Services revenue was $46.1 million, compared to $47.1 million in the third quarter of 2025.
- Net loss from continuing operations was $3.6 million, compared to a net loss of $4.8 million in the third quarter of 2025.
- Adjusted EBITDA was $30.2 million, compared to $28.6 million in the third quarter of 2025.
- Adjusted diluted earnings per share for the third quarter of 2026 was $0.09, compared to $0.09 for the third quarter of 2025.
Guidance
- 2026 full year revenue growth range: 2% to 3%
- Adjusted diluted earnings per share range: $0.31 to $0.34
- Fully diluted weighted average shares outstanding range: 155 million to 157 million
- Effective tax rate range: 25% to 30%
Notes
Financial results of the Regulatory and Medical Writing business are reported as discontinued operations; the Regulatory and Medical Writing business was divested on May 8, 2026.
Price and volatility reaction
The stock moved +9.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +23.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 11.09 | 2026-11-04 |
| Close after release | 12.18 | 2026-11-05 |
| Realised move | +9.8% | close to close |
| 30d ATM IV change | +23.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
